BioAtla Inc (NASDAQ: BCAB) kicked off on Tuesday, down -4.79% from the previous trading day, before settling in for the closing price of $1.67. Over the past 52 weeks, BCAB has traded in a range of $1.14-$4.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -56.91% over the past five years. While this was happening, its average annual earnings per share was recorded 40.93%. With a float of $39.02 million, this company’s outstanding shares have now reached $48.35 million.
Let’s look at the performance matrix of the company that is accounted for 65 employees. In terms of profitability, gross margin is 93.41%, operating margin of -678.7%, and the pretax margin is -643.92%.
BioAtla Inc (BCAB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BioAtla Inc is 19.30%, while institutional ownership is 32.74%. The most recent insider transaction that took place on Dec 26 ’23, was worth 9,320. In this transaction Director of this company bought 4,000 shares at a rate of $2.33, taking the stock ownership to the 15,125 shares. Before that another transaction happened on Dec 20 ’23, when Company’s Chief Executive Officer bought 50,000 for $2.14, making the entire transaction worth $106,910. This insider now owns 1,439,283 shares in total.
BioAtla Inc (BCAB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 40.93% per share during the next fiscal year.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
Take a look at BioAtla Inc’s (BCAB) current performance indicators. Last quarter, stock had a quick ratio of 3.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
BioAtla Inc (NASDAQ: BCAB) saw its 5-day average volume 0.44 million, a negative change from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 55.56%. Additionally, its Average True Range was 0.18.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 22.41%, which indicates a significant decrease from 24.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.74% in the past 14 days, which was higher than the 94.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8777, while its 200-day Moving Average is $2.0850. Nevertheless, the first resistance level for the watch stands at $1.6567 in the near term. At $1.7233, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7667. If the price goes on to break the first support level at $1.5467, it is likely to go to the next support level at $1.5033. The third support level lies at $1.4367 if the price breaches the second support level.
BioAtla Inc (NASDAQ: BCAB) Key Stats
The company with the Market Capitalisation of 76.87 million has total of 48,346K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -123,460 K annual income. Company’s last quarter sales were recorded 11,000 K and last quarter income was -10,590 K.
